NEW DATA FROM VASOGEN'S ACCLAIM TRIAL IN HEART FAILURE PRESENTED AT WORLD CONGRESS OF CARDIOLOGY 2006

Vasogen, a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, announced that new data from the 2,400-patient ACCLAIM trial in chronic heart failure showed that in a major combined subgroup of New York Heart Association (NYHA) Class III/IV patients with no prior history of heart attack and all Class II patients, together comprising more than 50% of the study population, Vasogen's Celacade technology reduced the risk of death and cardiovascular hospitalization by 31% (n= 1,305 patients, p=0.0003). Celacade was also shown to be safe and well tolerated.
Vasogen